Overcoming Limited Access to Virus Infection Rapid Testing: Development of a Lateral Flow Test for SARS-CoV-2 with Locally Available Resources

• Published in: Biosensors (Basel) Vol. 14; no. 9; p. 416
• Main Authors: Peri Ibáñez, Estefanía S., Mazzeo, Agostina, Silva, Carolina, Juncos, Maria Juliana, Costa Navarro, Guadalupe S., Pallarés, Horacio M., Wolos, Virginia J., Fiszman, Gabriel L., Mundo, Silvia L., Caramelo, Julio J., Yanovsky, Marcelo J., Fingermann, Matías, Castello, Alejandro A., Gamarnik, Andrea V., Peinetti, Ana S., Capdevila, Daiana A.
• Format: Journal Article
• Language: English
• Published: 27.08.2024
• ISSN: 2079-6374; 2079-6374
• DOI: 10.3390/bios14090416

The COVID-19 pandemic highlighted testing inequities in developing countries. Lack of lateral flow test (LFT) manufacturing capacity was a major COVID-19 response bottleneck in low- and middle-income regions. Here we report the development of an open-access LFT for SARS-CoV-2 detection comparable to commercial tests that requires only locally available supplies. The main critical resource is a locally developed horse polyclonal antibody (pAb) whose sensitivity and selectivity are greatly enhanced by affinity purification. We demonstrate that these Abs can perform similarly to commercial monoclonal antibodies (mAbs), as well as mAbs and other pAbs developed against the same antigen. We report a workflow for test optimization using nasopharyngeal swabs collected for RT-qPCR, spiked with the inactivated virus to determine analytical performance characteristics as the limit of detection, among others. Our final prototype showed a performance similar to available tests (sensitivity of 83.3% compared to RT-qPCR, and 90.9% compared to commercial antigen tests). Finally, we discuss the possibility and the challenges of utilizing affinity-purified pAbs as an alternative for the local development of antigen tests in an outbreak context and as a tool to address inequalities in access to rapid tests.